The effect of spirulina supplementation on MS

Investigating the effect of spirulina algae supplement on the quality of life, speed of nerve pulse transmission and antioxidant status of patients with progressive-recovery multiple sclerosis.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240124060794N1

Enrollment

Registered

2024-02-04

Start date

2024-04-18

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple sclerosis. Multiple sclerosis

Interventions

Intervention 1: Intervention group: spirulina algae supplement, 500 mg capsules, twice a day for three months, consumption after the main meal, Spiro Company (Bushehr-Iran). Intervention 2: Control gr

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Patients with MS of RRMS type Age of patients 18-50 years Receiving immunosuppressive drugs for at least three months Not taking multivitamin supplements (except vitamin D) at least 3 months before participating in the study Having an Extended Disability Status Scale (EDSS) between 0 and 6

Exclusion criteria

Exclusion criteria: Pregnancy Presentation of acute forms of liver and biliary system disease and pancreatic disease History of viral diseases Chronic renal or cardiovascular disease and diseases where oxidative stress is considered as their etiology Obese patients (body mass index (BMI) = 30 kg/m2), malnourished patients (BMI < 18.5 kg/m2) Dependence on drugs, smoking or alcohol Not taking anticoagulants Breastfeeding Hospitalized Autoimmune diseases that affect the Th1/Th2 balance Asthma Diseases in which oxidative stress is proposed as their etiology

Design outcomes

Primary

Measure	Time frame
Investigating antioxidant status. Timepoint: Before and after supplementation. Method of measurement: Biochemical kit for measurement of antioxidant level.;Investigating the quality of life and work. Timepoint: Before and after supplementation. Method of measurement: Quality of life questionnaire.;Investigating the speed of nerve transmission. Timepoint: Before and after supplementation. Method of measurement: Skin electrode.;Investigating the inflammation status. Timepoint: Before and after supplementation. Method of measurement: IL-1 and IL-6 measurement by ELISA.	—

Measure

Time frame

Investigating antioxidant status. Timepoint: Before and after supplementation. Method of measurement: Biochemical kit for measurement of antioxidant level.;Investigating the quality of life and work. Timepoint: Before and after supplementation. Method of measurement: Quality of life questionnaire.;Investigating the speed of nerve transmission. Timepoint: Before and after supplementation. Method of measurement: Skin electrode.;Investigating the inflammation status. Timepoint: Before and after supplementation. Method of measurement: IL-1 and IL-6 measurement by ELISA.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Hasan Entezari

Esfahan University of Medical Sciences

entezari@hlth.mui.ac.ir+98 31 3792 3172

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026